| [1] |
World Health Organization.Global tuberculosis report 2021[R].Geneva：WHO，2021.
URL
|
| [2] |
Gebrayel P, Nicco C, Al Khodor S, et al. Microbiota medicine：towards clinical revolution[J]. J Transl Med， 2022， 20(1)：111.DOI： 10.1186/s12967-022-03296-9.
|
| [3] |
Naidoo CC， Nyawo GR， Sulaiman I，et al.Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis[J]. EBioMedicine， 2021(67)：103374.DOI： 10.1016/j.ebiom.2021.103374.
|
| [4] |
Lavelle A, Hoffmann TW, Pham HP, et al. Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host[J]. Microbiome， 2019， 7(1)：111.DOI： 10.1186/s40168-019-0725-3.
|
| [5] |
Dudek-Wicher RK， Junka A， Bartoszewicz M．The influence of antibiotics and dietary components on gut microbiota[J]. Prz Gastroenterol， 2018， 13(2)：85-92.DOI： 10.5114/pg.2018.76005.
|
| [6] |
Hu Y， Yang Q， Liu B，et al.Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs[J]. J Infect， 2019， 78(4)：317-322.DOI： 10.1016/j.jinf.2018.08.006.
|
| [7] |
de Gunzburg J， Ghozlane A， Ducher A，et al.Protection of the human gut microbiome from antibiotics[J]. J Infect Dis， 2018， 217(4)：628-636.DOI： 10.1093/infdis/jix604.
|
| [8] |
侯美玲．抗结核药物对肠道菌群影响及干酪乳杆菌补充改善效果的实验研究[D].青岛：青岛大学，2021.
|
| [9] |
Namasivayam S， Maiga M， Yuan W，et al.Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy[J]. Microbiome， 2017， 5(1)：71.DOI： 10.1186/s40168-017-0286-2.
|
| [10] |
|
| [11] |
Vacca M， Celano G， Calabrese FM，et al.The controversial role of human gut lachnospiraceae[J]. Microorganisms， 2020， 8(4)：573.DOI： 10.3390/microorganisms8040573.
|
| [12] |
Cuskin F， Lowe EC， Temple MJ，et al.Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanism[J]. Nature， 2015， 517(7533)：165-169.DOI： 10.1038/nature13995.
|
| [13] |
李玉红．肠道菌群特征与抗结核药物性肝损伤的关系研究[D].唐山：华北理工大学，2020.
|
| [14] |
Hu Y, Feng Y, Wu J, et al. The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients[J]. Front Cell Infect Microbiol， 2019(9)：90.DOI： 10.3389/fcimb.2019.00090.
|
| [15] |
Wipperman MF， Fitzgerald DW， Juste M，et al.Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed[J]. Sci Rep， 2017， 7(1)：10767.DOI： 10.1038/s41598-017-10346-6.
|
| [16] |
Zhu W， Wang J， Zhao N，et al.Oral administration of Clostridium butyricum rescues streptomycin-exacerbated respiratory syncytial virus-induced lung inflammation in mice[J]. Virulence， 2021， 12(1)：2133-2148.DOI： 10.1080/21505594.2021.1962137.
|
| [17] |
Grayson MH， Camarda LE， Hussain SA，et al.Intestinal microbiota disruption reduces regulatory T cells and increases respiratory viral infection mortality through increased IFN-γ production[J]. Front Immunol， 2018(9)：1587.DOI： 10.3389/fimmu.2018.01587.
|
| [18] |
Dubourg G， Lagier C， Armougom F，et al.The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics[J]. Eur J Clin Microbiol Infect Dis， 2013， 32(5)：637-645.DOI： 10.1007/s10096-012-1787-1793.
|
| [19] |
Luo M， Liu Y， Wu P，et al.Alternation of gut microbiota in patients with pulmonary tuberculosis[J]. Front Physiol， 2017(8)：822.DOI： 10.3389/fphys.2017.00822.
|
| [20] |
Wang J, Xiong K, Zhao S, et al. Long-term effects of multi-drug-resistant tuberculosis treatment on gut microbiota and its health consequences[J]. Front Microbiol， 2020(11)：53.DOI： 10.3389/fmicb.2020.00053.
|
| [21] |
Burdet C， Nguyen TT， Duval X，et al.Impact of antibiotic gut exposure on the temporal changes in microbiome diversity[J]. Antimicrob Agents Chemother， 2019， 63(10)：e00820-19.DOI： 10.1128/AAC.00820-19.
|
| [22] |
Kelly SA， Nzakizwanayo J， Rodgers AM，et al.Antibiotic therapy and the gut microbiome：investigating the effect of delivery route on gut pathogens[J]. ACS Infect Dis， 2021， 7(5)：1283-1296.DOI： 10.1021/acsinfecdis.1c00081.
|
| [23] |
Gu SL， Gong Y， Zhang J，et al.Effect of the short-term use of fluoroquinolone and β-lactam antibiotics on mouse gut microbiota[J]. Infect Drug Resist， 2020(13)：4547-4558.DOI： 10.2147/IDR.S281274.
|
| [24] |
Chiu CC， Ching YH， Li YP，et al.Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis[J]. Nutrients， 2017， 9(11)：1220.DOI： 10.3390/nu9111220.
|
| [25] |
|
| [26] |
Chen Z， Zhou D， Han S，et al.Hepatotoxicity and the role of the gut-liver axis in rats after oral administration of titanium dioxide nanoparticles[J]. Part Fibre Toxicol， 2019， 16(1)：48.DOI： 10.1186/s12989-019-0332-2.
|
| [27] |
Saeedi BJ， Liu KH， Owens JA，et al.Gut-resident lactobacilli activate hepatic nrf2 and protect against oxidative liver injury[J]. Cell Metab， 2020， 31(5)：956-968.e5.DOI： 10.1016/j.cmet.2020.03.006.
|
| [28] |
|
| [29] |
刘庆香．吡嗪酰胺致肝损伤作用及其代谢受肠道菌群影响的研究[D].重庆：重庆医科大学，2021.
|
| [30] |
Xiong K, Cai J, Liu P, et al. Lactobacillus casei alleviated the abnormal increase of cholestasis-related liver indices during tuberculosis treatment：a post hoc analysis of randomized controlled trial[J]. Mol Nutr Food Res， 2021， 65(16)：e2100108.DOI： 10.1002/mnfr.202100108.
|
| [31] |
Hermans SM， Zinyakatira N， Caldwell J，et al.High rates of recurrent tuberculosis disease：a population-level cohort study[J]. Clin Infect Dis， 2021， 72(11)：1919-1926.DOI： 10.1093/cid/ciaa470.
|
| [32] |
Negi S， Pahari S， Bashir H，et al.Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice[J]. Eur J Immunol， 2020， 50(12)：1976-1987.DOI： 10.1002/eji.202048556.
|
| [33] |
Khan N, Mendonca L, Dhariwal A, et al. Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis[J]. Mucosal Immunol， 2019， 12(3)：772-783.DOI： 10.1038/s41385-019-0147-3.
|
| [34] |
Teame T， Wang A， Xie M，et al.Paraprobiotics and postbiotics of probiotic Lactobacilli，their positive effects on the host and action mechanisms：a review[J]. Front Nutr， 2020(7)：570344.DOI： 10.3389/fnut.2020.570344.
|
| [35] |
Saha UB， Saroj SD.Lactic acid bacteria：prominent player in the fight against human pathogens[J]. Expert Rev Anti Infect Ther， 2022， 20(11)：1435-1453.DOI： 10.1080/14787210.2022.2128765.
|
| [36] |
Eribo OA, du Plessis N, Ozturk M, et al. The gut microbiome in tuberculosis susceptibility and treatment response：guilty or not guilty？[J]. Cell Mol Life Sci， 2020， 77(8)：1497-1509.DOI： 10.1007/s00018-019-03370-4.
|
| [37] |
Takahashi K， Nishida A， Fujimoto T，et al.Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in crohn′s disease[J]. Digestion， 2016， 93(1)：59-65.DOI： 10.1159/000441768.
|
| [38] |
Khaliq A， Ravindran R， Afzal S，et al.Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting[J]. PLoS One， 2021， 16(1)：e245534.DOI： 10.1371/journal.pone.0245534.
|
| [39] |
Sandberg J， Kovatcheva-Datchary P， Björck I，et al.Abundance of gut Prevotella at baseline and metabolic response to barley prebiotics[J]. Eur J Nutr， 2019， 58(6)：2365-2376.DOI： 10.1007/s00394-018-1788-9.
|